Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
暂无分享,去创建一个
[1] A. Feldstein,et al. Caspase 1-mediated regulation of fibrogenesis in diet-induced steatohepatitis , 2011, Laboratory Investigation.
[2] A. Feldstein,et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. , 2011, Journal of hepatology.
[3] A. Kahraman,et al. Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes , 2010, Digestion.
[4] F. Berthier,et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin‐18 for the diagnosis of non‐alcoholic steatohepatitis in morbidly obese patients , 2010, Alimentary pharmacology & therapeutics.
[5] M. Hussain,et al. Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD , 2010, Journal of pediatric gastroenterology and nutrition.
[6] S. Friedman,et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. , 2010, Gastroenterology.
[7] H. Thomas,et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. , 2010, Journal of hepatology.
[8] G. Gores,et al. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. , 2010, American journal of physiology. Gastrointestinal and liver physiology.
[9] G. Gores,et al. Hepatocyte death: a clear and present danger. , 2010, Physiological reviews.
[10] E. Schiff,et al. Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C , 2010, Alimentary pharmacology & therapeutics.
[11] G. Gores,et al. 779 PF-03491390 PAN-CASPASE INHIBITOR DECREASES LIVER INJURY AND FIBROSIS IN A MURINE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) , 2010 .
[12] R. Levine,et al. 84 SAFETY, TOLERABILITY AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) , 2010 .
[13] G. Musso,et al. Noninvasive assessment of liver disease severity with liver fat score and CK‐18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation , 2010, Hepatology.
[14] A. Chervonsky,et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. , 2010, The Journal of clinical investigation.
[15] P. Schauer,et al. Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis* , 2009, The Journal of Biological Chemistry.
[16] Vanessa S Teaberry,et al. Pan‐caspase inhibitor VX‐166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis , 2009, Hepatology.
[17] A. Kahraman,et al. Apoptosis is associated with CD36/fatty acid translocase upregulation in non‐alcoholic steatohepatitis , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[18] A. Feldstein,et al. Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.
[19] G. Gores,et al. Mcl-1 Degradation during Hepatocyte Lipoapoptosis* , 2009, The Journal of Biological Chemistry.
[20] A. Feldstein,et al. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal , 2009, Expert review of gastroenterology & hepatology.
[21] G. Gores,et al. Matrix metalloproteinase inhibitor, CTS‐1027, attenuates liver injury and fibrosis in the bile duct‐ligated mouse , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[22] G. Gores,et al. JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis* , 2009, The Journal of Biological Chemistry.
[23] Lifen Gao,et al. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease , 2009, Immunogenetics.
[24] Dong Wang,et al. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells , 2009, Molecular and Cellular Biochemistry.
[25] C. Nolan,et al. Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it? , 2009, Journal of gastroenterology and hepatology.
[26] A. Feldstein,et al. 566 An Apoptosis Panel for Nonalcoholic Steatohepatitis Diagnosis , 2009 .
[27] D. Schuppan,et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease , 2009, Journal of gastroenterology and hepatology.
[28] A. Feldstein,et al. Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease , 2009, Journal of Biological Chemistry.
[29] G. Gores,et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. , 2008, Gastroenterology.
[30] A. Diehl,et al. Mechanisms of disease progression in nonalcoholic fatty liver disease. , 2008, Seminars in liver disease.
[31] P. Schauer,et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] Ming Yan,et al. Prevention of free fatty acid–induced hepatic lipotoxicity by 18β‐glycyrrhetinic acid through lysosomal and mitochondrial pathways , 2008, Hepatology.
[33] A. Baranova,et al. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) , 2008, Obesity surgery.
[34] G. Gores,et al. Cellular and molecular mechanisms of liver injury. , 2008, Gastroenterology.
[35] G. Gores,et al. The lysosomal‐mitochondrial axis in free fatty acid–induced hepatic lipotoxicity , 2008, Hepatology.
[36] G. Gores,et al. TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse , 2008, Hepatology.
[37] Ramesh Natarajan,et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. , 2008, Gastroenterology.
[38] D. A. Gomes,et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll‐like receptor 9 , 2007, Hepatology.
[39] G. Gores,et al. Death receptor-mediated liver injury. , 2007, Seminars in liver disease.
[40] G. Gores,et al. Transcriptional Regulation of Bim by FoxO3A Mediates Hepatocyte Lipoapoptosis* , 2007, Journal of Biological Chemistry.
[41] G. Michalopoulos,et al. Lack of Fas antagonism by Met in human fatty liver disease , 2007, Nature Medicine.
[42] David Hecht,et al. Oral IDN‐6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C , 2007, Hepatology.
[43] C. McClain,et al. Good fat/bad fat , 2007, Hepatology.
[44] S. McCall,et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.
[45] G. Gores,et al. cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[46] G. Gores,et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity , 2007, Gut.
[47] Dong Wang,et al. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells , 2007, Molecular and Cellular Biochemistry.
[48] E. Ulukaya,et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. , 2007, World journal of gastroenterology.
[49] S. Lipkowitz,et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract , 2007, Apoptosis.
[50] B. Sharma,et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.
[51] A. Colell,et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. , 2006, Cell metabolism.
[52] Dong Wang,et al. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. , 2006, American journal of physiology. Endocrinology and metabolism.
[53] Lisa M Yerian,et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.
[54] G. Gores,et al. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. , 2006, American journal of physiology. Gastrointestinal and liver physiology.
[55] G. Gores,et al. Free Fatty Acids Induce JNK-dependent Hepatocyte Lipoapoptosis* , 2006, Journal of Biological Chemistry.
[56] M. Pagliassotti,et al. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. , 2006, Endocrinology.
[57] J. Olefsky,et al. Inflamed fat: what starts the fire? , 2005, The Journal of clinical investigation.
[58] G. Gores,et al. Death by association: BH3 domain-only proteins and liver injury. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[59] A. Feldstein,et al. Nonalcoholic fatty liver disease in the pediatric population: a review , 2005, Current opinion in pediatrics.
[60] G. Gores,et al. Apoptosis in alcoholic and nonalcoholic steatohepatitis. , 2005, Frontiers in bioscience : a journal and virtual library.
[61] J. Lemasters. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. , 2005, Gastroenterology.
[62] G. Gores,et al. Apoptosis: a mechanism of acute and chronic liver injury , 2005, Gut.
[63] D. Green,et al. Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.
[64] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[65] G. Gores,et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[66] D. Ron,et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. , 2004, Genes & development.
[67] K. Lindor,et al. A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis , 2004, The American Journal of Gastroenterology.
[68] Yigong Shi,et al. Molecular mechanisms of caspase regulation during apoptosis , 2004, Nature Reviews Molecular Cell Biology.
[69] Xiao-Ming Yin,et al. Dissection of the multiple mechanisms of TNF‐α‐induced apoptosis in liver injury , 2004 .
[70] Takahiro Suzuki,et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. , 2004, Gastroenterology.
[71] Amy S. Lee,et al. Transgenic mouse model for monitoring endoplasmic reticulum stress in vivo , 2004, Nature Medicine.
[72] H. Cortez‐Pinto,et al. Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients , 2004, The American Journal of Gastroenterology.
[73] L. Krugner-Higby,et al. Mitochondria in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.
[74] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[75] G. Gores,et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .
[76] J. Kench,et al. Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.
[77] G. Gores,et al. Lysosomes in cell death , 2004, Oncogene.
[78] D. Pessayre,et al. The ins and outs of mitochondrial dysfunction in NASH. , 2004, Diabetes & metabolism.
[79] D. Bredesen,et al. Coupling endoplasmic reticulum stress to the cell death program , 2004, Cell Death and Differentiation.
[80] G. Gores,et al. The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse , 2004, Journal of Pharmacology and Experimental Therapeutics.
[81] G. Gores,et al. Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.
[82] H. Horvitz,et al. A first insight into the molecular mechanisms of apoptosis , 2004, Cell.
[83] M. Desai,et al. Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.
[84] G. Gores,et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. , 2003, Journal of hepatology.
[85] M. Diederich,et al. An Introduction to the Molecular Mechanisms of Apoptosis , 2003, Annals of the New York Academy of Sciences.
[86] Suzanne Cory,et al. The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.
[87] K. Valentino,et al. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. , 2003, International journal of clinical pharmacology and therapeutics.
[88] J. Eaton,et al. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. , 2003, European journal of biochemistry.
[89] G. Gores,et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.
[90] J. Tschopp,et al. Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.
[91] G. Gores,et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.
[92] G. Kroemer,et al. Lysosomal Membrane Permeabilization Induces Cell Death in a Mitochondrion-dependent Fashion , 2003, The Journal of experimental medicine.
[93] R. Kaufman,et al. The unfolded protein response , 2003, Journal of Cell Science.
[94] G. Gores,et al. Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic , 2003, Laboratory Investigation.
[95] M. MacFarlane. TRAIL-induced signalling and apoptosis. , 2003, Toxicology letters.
[96] A. Moser,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.
[97] G. Gores,et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. , 2002, Gastroenterology.
[98] S. Cory,et al. The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.
[99] G. Gores,et al. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. , 2001, The American journal of pathology.
[100] J. Crespo,et al. Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .
[101] S. Itohara,et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy , 2001, Nature Medicine.
[102] R. Youle,et al. Bax and Bak Coalesce into Novel Mitochondria-Associated Clusters during Apoptosis , 2001, The Journal of cell biology.
[103] Marcel Leist,et al. Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.
[104] J. Martinou,et al. Bax Is Present as a High Molecular Weight Oligomer/Complex in the Mitochondrial Membrane of Apoptotic Cells* , 2001, The Journal of Biological Chemistry.
[105] L. Ellerby,et al. Lysosomal Protease Pathways to Apoptosis , 2001, The Journal of Biological Chemistry.
[106] G. Gores,et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. , 2000, The Journal of clinical investigation.
[107] G. Gores,et al. Apoptosis and liver disease. , 2000, The American journal of medicine.
[108] F. Urano,et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. , 2000, Science.
[109] G. Gores,et al. Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis , 1999, Hepatology.
[110] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[111] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[112] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[113] M. Omary,et al. Apoptosis Generates Stable Fragments of Human Type I Keratins* , 1997, The Journal of Biological Chemistry.
[114] G. Gores,et al. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. , 1997, Gastroenterology.
[115] G. Salvesen,et al. Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis , 1997, The Journal of cell biology.
[116] J. Kos,et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. , 1995, Biological chemistry Hoppe-Seyler.
[117] C. Surawicz,et al. Editorial: Clostridium difficile Infection: Yet Another Predictor of Poor Outcome in Cirrhosis , 2010, The American Journal of Gastroenterology.
[118] M. Pagliassotti,et al. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells , 2009, Molecular and Cellular Biochemistry.
[119] G. Gores,et al. Cathepsins as effector proteases in hepatocyte apoptosis , 2007, Cell Biochemistry and Biophysics.
[120] M. Pinzani. Liver fibrosis , 2004, Springer Seminars in Immunopathology.
[121] S. Friedman,et al. Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.
[122] M. Peter,et al. The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.
[123] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.